A moxifloxacin-based regimen for the treatment of recurrent drug-sensitive pulmonary tuberculosis: An open-label randomised controlled trial
Abstract
The substitution of moxifloxacin for ethambutol produced promising results for improved tuberculosis (TB) treatment outcomes. We conducted an open-label randomized trial to test whether a moxifloxacin-containing treatment regimen was superior to the standard regimen for the treatment of recurrent TB. The primary and secondary outcomes were sputum culture conversion rate at the end of 8 weeks and the proportion of participants with a favourable outcome, respectively. We enrolled 196 participants; 69.9% were male and 70.4% were co-infected with HIV. There was no significant difference between the study groups in the proportion of patients achieving culture conversion at the end of 8 weeks [83.0% (Moxifloxacin) vs 78.5% (Control), p=0.463], however the median time to culture conversion was significantly shorter (6.0 weeks, IQR 4.0 - 8.3) in the moxifloxacin group than the control group (7.9 weeks, IQR 4.0- 11.4) (p=0.018). A favourable end-of-treatment outcome was reported in 86 participants (87.8%) in the moxifloxacin group and 93 participants (94.9%) in the control group, for an adjusted absolute risk difference of -5.5 (95% CI -13.8 to 2.8, p=0.193) percentage points. There was a significantly higher proportion of participants ...Continue Reading
Associated Clinical Trials
References
A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis
Citations
Related Concepts
Related Feeds
Antitubercular Agents
Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.
Antitubercular Agents (ASM)
Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.